Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Abroad (travel likely)RecruitingPHASE3

Conditions

Gastric Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Affiliated Hospital, Academy of Military Medical Sciences, Beijing, China
Contact: Study coordinator (Jianming Xu, PhD)

Study leads

Jianming Xu, Ph.D
Principal Investigator
Affiliated Hospital, Academy of Military Medical Sciences

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Gastric Cancer · Gastroesophageal Junction Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Beijing, China · Xiamen, China

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

Recurrent Ovarian Cancer · HER2-negative · Advanced Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Shanghai, China

Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence

Gastric Cancer

Abroad (travel likely)RecruitingPHASE3

Krakow, Poland

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China · Guiyang, China